

"New Indications for Ultiva"

GlaxoSmithKline recently obtained registration for the dosages of Ultiva in Paediatric & Cardiac procedures, as well as the use of Ultiva in the ICU. To introduce the new indications to the profession, a number of regional launches were held recently. The presentations highlighted the benefits of Ultiva in these settings and were very well received.

According to Jaco de Wet, outgoing brand manager for Ultiva, the recent approval of these indications proves that Ultiva has come of age, and the range of patients it can be used in, is continually expanding. It further shows that GSK is committed to Anaesthesia, seeking more ways to deliver innovative therapies to the profession.

For further information, please contact Annette Niemann, Brand Manager for Ultiva on (011) 745-6390.



Prof Bosenberg, presenting on the use of Ultiva in paediatric patients



Dr Bill Wilson during his presentation in Cape Town



Dr Johann Dreyer, addressing the audience on the use of Ultiva in Cardiac patients



Prof Coetzee, chairperson of the Cape Town regional meeting, commenting on the success Ultiva had since launching in SA in 1999



Dr Zane Farina, sharing his knowledge on ICU sedation, with special reference to Ultiva